Hla Dr4 Antibodies Cause Positive HTLV-Iii Antibody Elisa Results

Self Cite

In a survey on 82,383 blood donor specimens from Hessen, West Germany, the observed percentage of repeatedly positive HTLV-III/LAV antibody ELISA results was 0.2%, but only 0.018% were confirmed by Western blot, immunofluorescence assay or radioimmunoprecipitation assay. These data are consistent with larger epidemiological data compiled from other German blood banks and suggest a high degree of nonspecific false-positive results; one of the causes for false-positives are HLA-DR4 antibodies, which react in the HTLV-III/LAV test. Epidemiological data on 127 dialysis patients and 1,153 prison inmates are presented.

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Anti-HTLV-III Screening of Blood Donors

Kühnl¹,

Seidl²,

Holzberger³

1986

Self Cite

“…On a theoretical basis, we might expect that these kits would perform in a similar fashion, particularly since some false positive results are due to HLA antibodies reacting with HLA class II anti gens expressed by the H9 cell line [9,10]. Perhaps most convincingly, 9 months of experience in blood donor screening using the first 3 US FDA licensed test kits (Abbott, ENI, Litton) indicate that the WB confirmation rate of anti-HTLV III ELISA-positive samples is similar for all 3 kits.…”

Section: Methodsmentioning

confidence: 99%

Anti-HTLV III ELISA and Western Blot Testing in a Blood Donor Population: Implications for Donor Notification

Kleinman¹,

Anton-Guirgis²,

Culver³

et al. 1986

We have evaluated the western blot (WB) test for distinguishing anti-HTLV III ELISA-positive donors who have likely been exposed to HTLV III from those that are false positives. Of 1,955 donors, 26 were positive for anti-HTLV III by ELISA testing. Only 6 (23%) were positive by WB: 5 of these 6 were male homosexuals with multiple partners and 5 of 6 had low Th/Ts ratios. The WB-positive donors gave the highest absorbance values in the anti-HTLV III ELISA assay. The immunologic abnormalities in the WB-positive donors suggest that they should be notified of their test results. We conclude that basing a donor notification policy on WB results is the optimum public health strategy for blood banks at the present time.

“…anti-HIV EIA-reactive specimens are false positives [6] due to storage alteration, resulting in 'stickiness' of sera [7], due to photometric reading at only one wavelength (492 nm) instead of bichromatical reading with 492-and 690-nm filters [8], or due to HLA antibodies [9], we included these parameters in our evaluation of the blood specimens. Repeatedly reactive (=EIA-positive) samples were evalu ated bichromatically at 492 and 690 mn by the microelisa processor (Behring EIA), screened for HLA antibodies and further tested by the Organon Teknika EIA, the 'VIRGO' (Viramed/ENI) and the 'ELAV IA' (AHS/Merz and Dade) EIAs; the latter two compare the absorp tion values of LAV-infected versus uninfected CEM cells ('Pasteur antigen') and H9 cells, respectively.…”

Section: Introductionmentioning

confidence: 99%

Human Immunodeficiency Virus Antibody Screening in Blood Donors from India, Nigeria and Thailand

Seidl¹,

Ray²,

Kulkarni³

et al. 1987

Self Cite

Screening for human immunodeficiency virus (HIV) (LAV/HTLV-III) antibodies in 3 blood donor populations from India (n= 1,000), Nigeria (n=500) and Thailand (n=650; sampling in 1982) with a sensitive enzyme immunoassay (EIA; Abbott) yielded seropositivity rates of 0.5, 2.2 and 1.7%, respectively. Two EIAs with control antigens prepared from uninfected cell cultures (‘ELAVIA’, VIRGO’), a recombinant Escherichia coli DNA EIA (‘ENV/CORE’), Western blot, an immunofluorescence assay and a radio-immunoprecipitation assay confirmed none of the EIA-reactive specimens as truly positive. The lack of specificity of the screening test was also attributable to monochromatic evaluation of the test trays at 492 nm only, and to reactivities against determinants of H9 cells used to grow HIV (HLA antibodies).